SurVaxM misses overall survival endpoint in glioblastoma trial

An experimental peptide vaccine for newly diagnosed glioblastoma missed its primary overall-survival endpoint in a randomized trial, according to results announced October 7 by MimiVax and Roswell Park Comprehensive Cancer Center. The finding qualifies encouraging earlier research and leaves the treatment’s clinical benefit unresolved, despite a favorable signal in younger participants.

The Phase 2b SURVIVE study compared SurVaxM with placebo alongside standard care. Among 233 evaluable patients, median overall survival was 22.8 months with the vaccine and 20.3 months with placebo. Fierce Biotech independently reported the missed endpoint and the developer’s intention to pursue further regulatory discussions.

### What the randomized comparison showed

SURVIVE was a double-blind, multicenter trial. Overall survival—the primary endpoint—measures how long participants remain alive, making it a direct clinical outcome rather than a laboratory marker of biological activity.

The reported hazard ratio for death was 0.75, with a 95% confidence interval of 0.54 to 1.03 and a p-value of 0.076. The interval includes 1, the value representing no difference between groups, and the result did not meet the conventional statistical-significance threshold.

A numerical separation between median survival times does not establish that treatment caused the difference. Conversely, missing the threshold does not prove that the vaccine has no effect. The result leaves uncertainty about the size and reliability of any benefit.

### A subgroup signal needs careful interpretation

The investigators highlighted patients aged 65 and younger, describing this group as prespecified. Median survival was 24.2 months with SurVaxM versus 20.2 months with placebo; the reported hazard ratio was 0.64, with a p-value of 0.019.

Selecting a subgroup before analysis is more informative than discovering one after examining results. Nevertheless, a favorable subgroup finding does not automatically overturn an unsuccessful primary comparison. Assessing its strength requires the statistical analysis plan, information about adjustments for multiple comparisons and evidence about whether treatment effects actually differ by age.

The announcement does not provide enough detail to settle those questions. It therefore supports further testing of an age-related signal, without establishing an age cutoff for clinical use.

### Why earlier evidence was insufficient

SurVaxM is a peptide vaccine conjugate directed against survivin, a protein expressed by glioblastoma cells. Its intended action is to stimulate immune recognition of cancer cells carrying that target.

An earlier open-label Phase 2a study enrolled 64 patients and combined the vaccine with temozolomide after surgery and chemoradiation. Published online in December 2022 in the Journal of Clinical Oncology, that study documented survivin-specific immune responses and reported median overall survival of 25.9 months from the first vaccine dose.

However, the earlier study had no randomized control group. Its survival estimate could not isolate the vaccine’s contribution from patient selection, accompanying treatment or other factors. The newer placebo-controlled comparison addresses that central limitation. Survival figures from the two studies should not be treated as interchangeable benchmarks.

### Safety and the development path

The October announcement reported Grade 3 or higher adverse events in 48% of vaccine recipients and 46% of placebo recipients. These are overall event rates during cancer treatment, not percentages of events established as vaccine-caused.

MimiVax plans to discuss the findings with the FDA. SurVaxM remains investigational, and a planned regulatory meeting is not an approval decision. The practical development question is whether fuller analysis and additional controlled evidence can confirm a meaningful benefit while adequately characterizing harms.